Florian Markowetz

FMedSci
Alma materHeidelberg University, Free University of Berlin
Scientific career
InstitutionsCancer Research UK Cambridge Institute, University of Cambridge, Tailor Bio
Thesis (2006)
Websitewww.cruk.cam.ac.uk/research-groups/markowetz-group

Florian Markowetz is the Professor of Computational Oncology at the University of Cambridge.[1] He is a Senior Group Leader at the Cancer Research UK Cambridge Institute and Director and co-founder of Tailor Bio, a genomics company aiming to improve precision medicine for cancers with high levels of chromosomal instability.[2][3]

Education

Markowetz has degrees in Mathematics and Philosophy from Heidelberg University and completed his PhD in Computational Biology from the Free University of Berlin, for which he was awarded an Otto-Hahn Medal by the Max Planck Society.[4]

Research and career

Markowetz's research combines machine learning and artificial intelligence with experimental techniques ranging from single cell sequencing to tissue imaging to understand the mechanisms behind chromosomal instability; how to target cancer weaknesses with therapies; how to overcome resistance to treatment; and how to improve the early detection of cancer.

His team have developed a compendium of 17 copy number signatures characterising different types of chromosomal instability. These chromosomal instability signatures were able to predict how tumours might respond to drugs, as well as helping in the identification of future drug targets.[5][6][7][8][9][10] This research has led to the formation of Tailor Bio, a genomics company which aims to build a new pan-cancer precision medicine platform.[11]

Markowetz's research has created artificial intelligence approaches to analyse data from the Cytosponge, a minimally invasive device to detect a precursor of oesophageal cancer. This work automates labour-intensive tasks and refines pathology biomarkers to identify the patients at the highest risk of developing cancer.[12][13][14]

Awards and honours

In 2016, Professor Markowetz was awarded the Future Leaders in Cancer Research Prize by Cancer Research UK. He was commended for his collaborative approach to research and his role as a champion of open science.[15]

Professor Markowetz received the Royal Society Wolfson Research Merit Award in 2017.[16]

References

  1. ↑ Brockley, Branwen (2022-06-15). "Institute Group Leaders awarded promotions by the University". Cancer Research UK Cambridge Institute. Retrieved 2023-08-11.
  2. ↑ "Markowetz group". Cancer Research UK Cambridge Institute. Retrieved 2023-08-11.
  3. ↑ Bio, Tailor. "Tailor Bio". Tailor Bio. Retrieved 2023-08-11.
  4. ↑ "Dr Florian Markowetz - Networks of evidence and expertise for public policy". www.csap.cam.ac.uk. Retrieved 2023-08-11.
  5. ↑ Drews, Ruben M.; Hernando, Barbara; Tarabichi, Maxime; Haase, Kerstin; Lesluyes, Tom; Smith, Philip S.; Morrill Gavarró, Lena; Couturier, Dominique-Laurent; Liu, Lydia; Schneider, Michael; Brenton, James D.; Van Loo, Peter; Macintyre, Geoff; Markowetz, Florian (June 2022). "A pan-cancer compendium of chromosomal instability". Nature. 606 (7916): 976–983. Bibcode:2022Natur.606..976D. doi:10.1038/s41586-022-04789-9. ISSN 1476-4687. PMC 7613102. PMID 35705807.
  6. ↑ Macintyre, Geoff; Goranova, Teodora E.; De Silva, Dilrini; Ennis, Darren; Piskorz, Anna M.; Eldridge, Matthew; Sie, Daoud; Lewsley, Liz-Anne; Hanif, Aishah; Wilson, Cheryl; Dowson, Suzanne; Glasspool, Rosalind M.; Lockley, Michelle; Brockbank, Elly; Montes, Ana (September 2018). "Copy number signatures and mutational processes in ovarian carcinoma". Nature Genetics. 50 (9): 1262–1270. doi:10.1038/s41588-018-0179-8. ISSN 1546-1718. PMC 6130818. PMID 30104763.
  7. ↑ Vias, Maria; Morrill Gavarró, Lena; Sauer, Carolin M.; Sanders, Deborah A.; Piskorz, Anna M.; Couturier, Dominique-Laurent; Ballereau, Stéphane; Hernando, Bárbara; Schneider, Michael P.; Hall, James; Correia-Martins, Filipe; Markowetz, Florian; Macintyre, Geoff; Brenton, James D. (2023-05-11). "High-grade serous ovarian carcinoma organoids as models of chromosomal instability". eLife. 12: e83867. doi:10.7554/eLife.83867. ISSN 2050-084X. PMC 10174694. PMID 37166279.
  8. ↑ Cheng, Zhao; Mirza, Hasan; Ennis, Darren P.; Smith, Philip; Morrill Gavarró, Lena; Sokota, Chishimba; Giannone, Gaia; Goranova, Theodora; Bradley, Thomas; Piskorz, Anna; Lockley, Michelle; BriTROC-1 Investigators; Kaur, Baljeet; Singh, Naveena; Tookman, Laura A. (2022-07-01). "The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma". Clinical Cancer Research. 28 (13): 2911–2922. doi:10.1158/1078-0432.CCR-21-1643. ISSN 1557-3265. PMC 7612959. PMID 35398881.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  9. ↑ Jiménez-Sánchez, Alejandro; Cybulska, Paulina; Mager, Katherine LaVigne; Koplev, Simon; Cast, Oliver; Couturier, Dominique-Laurent; Memon, Danish; Selenica, Pier; Nikolovski, Ines; Mazaheri, Yousef; Bykov, Yonina; Geyer, Felipe C.; Macintyre, Geoff; Gavarró, Lena Morrill; Drews, Ruben M. (June 2020). "Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy". Nature Genetics. 52 (6): 582–593. doi:10.1038/s41588-020-0630-5. ISSN 1546-1718. PMC 8353209. PMID 32483290.
  10. ↑ Shaw, Neil (2022-06-19). "Cancer breakthrough as scientists could create therapy for deadliest disease". WalesOnline. Retrieved 2023-08-11.
  11. ↑ "Tumour 'signatures' could provide key to more accurate treatment for deadliest cancers". University of Cambridge. 2022-06-15. Retrieved 2023-08-11.
  12. ↑ Gehrung, Marcel; Crispin-Ortuzar, Mireia; Berman, Adam G.; O'Donovan, Maria; Fitzgerald, Rebecca C.; Markowetz, Florian (May 2021). "Triage-driven diagnosis of Barrett's esophagus for early detection of esophageal adenocarcinoma using deep learning". Nature Medicine. 27 (5): 833–841. doi:10.1038/s41591-021-01287-9. ISSN 1546-170X. PMID 33859411. S2CID 233259832.
  13. ↑ Berman, Adam G.; Tan, W. Keith; O'Donovan, Maria; Markowetz, Florian; Fitzgerald, Rebecca C. (August 2022). "Quantification of TFF3 expression from a non-endoscopic device predicts clinically relevant Barrett's oesophagus by machine learning". eBioMedicine. 82: 104160. doi:10.1016/j.ebiom.2022.104160. ISSN 2352-3964. PMC 9297109. PMID 35843173.
  14. ↑ "Cambridge researchers use artificial intelligence to help detect early stage cancer". ITV Anglia. 28 April 2021.
  15. ↑ "Future Leaders in Cancer Research Prize". Cancer Research UK. 2015-10-28. Retrieved 2023-08-11.
  16. ↑ "Florian Markowetz, University of Cambridge: "A pan-cancer compendium of chromosomal instability"". www.cecad.uni-koeln.de. Retrieved 2023-08-11.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.